New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 22, 2014
10:01 EDTMOBL, SPCB, CFI, NSTG, TECHOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Bio-Techne (TECH) initiated with an Overweight at Stephens... Culp (CFI) initiated with a Buy at Stifel... MobileIron (MOBL) initiated with an Outperform at Imperial Capital... NanoString (NSTG) management to meet with Piper Jaffray... SuperCom (SPCB) initiated with an Outperform at Imperial Capital.
News For TECH;CFI;MOBL;NSTG;SPCB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
07:09 EDTMOBLBlackBerry announces Ocean Capital Investments migrates to BES12
BlackBerry (BBRY) announced that Ocean Capital Investments, and its subsidiaries, members of the Irving family of companies, are migrating to BES12: a cross-platform EMM solution by BlackBerry. Ocean Capital Investments will be deploying BES12 as a BlackBerry hosted cloud solution to manage BlackBerry and iOS devices, displacing their former mobile device management provider, MobileIron (MOBL). Ocean Capital Investments will replace the majority of their Apple (AAPL) iOS devices with BlackBerry's best-in-class QWERTY keyboard smartphones, BlackBerry Passport and the newly launched BlackBerry Classic.
December 10, 2014
10:00 EDTTECHOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:30 EDTTECHBio-Techne upgraded to Buy at Janney Capital
Subscribe for More Information
06:22 EDTTECHBio-Techne upgraded to Buy from Neutral at Janney Capital
Subscribe for More Information
December 8, 2014
16:07 EDTNSTGNanoString updates Prosigna FDA labeling
NanoString Technologies announced that the FDA has cleared a labeling update for the Prosigna Breast Cancer Gene Signature Assay. The labeling update is derived from the analysis of data by researchers from the Austrian Breast and Colorectal Cancer Study Group Trial 8, or ABCSG-8, who previously reported that the Prosigna Assay accurately assessed the probability of distant recurrence in postmenopausal women with Estrogen Receptor-Positive, or ER+, early-stage breast cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use